1. Home
  2. OPRA vs MPLT Comparison

OPRA vs MPLT Comparison

Compare OPRA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Opera Limited

OPRA

Opera Limited

HOLD

Current Price

$19.29

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

BUY

Current Price

$38.39

Market Cap

1.3B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
OPRA
MPLT
Founded
1996
2018
Country
Norway
United States
Employees
N/A
133
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
OPRA
MPLT
Price
$19.29
$38.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$21.50
$32.67
AVG Volume (30 Days)
335.1K
477.1K
Earning Date
04-28-2026
05-28-2026
Dividend Yield
4.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$21.29
N/A
Revenue Next Year
$15.34
N/A
P/E Ratio
$13.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.71
$12.24
52 Week High
$21.06
$39.91

Technical Indicators

Market Signals
Indicator
OPRA
MPLT
Relative Strength Index (RSI) 53.61 65.36
Support Level $16.96 $26.20
Resistance Level $19.43 N/A
Average True Range (ATR) 0.71 2.80
MACD -0.02 0.66
Stochastic Oscillator 51.41 83.61

Price Performance

Historical Comparison
OPRA
MPLT

About OPRA Opera Limited

Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: